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Effect of salt supplementation on amphotericin B nephrotoxicity. It has
been suggested that salt loading protects against amphotericin B-in-
duced nephrotoxicity. The influence of saline loading on the nephro-
toxic response to amphotericin 8 (50 mg/dose given i.v. over 4 hr 3
x/week for 10 weeks) was assessed in two groups of ten patients each
who were diagnosed with mucocutaneous leishmaniasis. Patients were
randomized to receive either I liter of 0.9% saline or I liter of 5%
dextrose in water, administered i.v. over one hour in a double-blinded
manner, directly prior to amphotericin B administration. Renal function
was monitored on a weekly basis two days after the last dose of
amphotericin B. Baseline characteristics were similar in both groups
except for a slightly higher serum creatinine concentration (Cr) in the
saline group (0.8 0.05 vs. 0.6 0.04 mg/dl). Baseline sodium (Na)
excretion was relatively high (262 23 mmol/day in the dextrose group
and 224 17 mmollday in the saline group). None of the patients
sustained an increase in Cr to values greater than 1.7 mg/dl. Although
mean Cr remained within normal, there was a significant difference
between the two groups over the ten week period, with the dextrose
group sustaining a significant increase in Cr and the saline group
remaining unchanged. Serum potassium (K) levels fell in both groups
necessitating oral K supplementation. The saline group required signif-
icantly greater amounts of K supplementation to maintain a normal
serum K. Amphotericin B caused a rapid reduction in the acidification
ability of the kidney in response to an ammonium chloride load. Under
these conditions, the saline group had a poorer ability to acidify the
urine. Urine volumes were not different between the two groups, and
the specific gravity of the urine sustained a significant and similar
decrease in the two groups. Neither plasma trough amphotericin B
levels nor tissue concentrations at the site of the lesion were different
between the two groups, suggesting that the effect of salt is probably not
on the basis of pharmacokinetic changes. This study supports the
hypothesis that salt loading confers protection against reductions in
renal function by amphotericin B, but does so at the expense of
enhancing K loss. The lower overall incidence of nephrotoxicity in
comparison to prior published experience could be due to racial
variation in responsiveness, the high baseline salt intake, or lack of
coadministration of other nephrotoxic drugs.
Nephrotoxicity has been recognized as a serious and com-
mon complication of amphotericin B use since the introduction
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of this drug in the 1950's. Early reports indicated that as many
as 80 to 90% of patients who received the drug developed some
degree of renal dysfunction [1—3]. The clinical presentation of
nephrotoxicity includes azotemia, renal tubular acidosis, im-
paired concentrating ability, and renal sodium, potassium and
magnesium wasting, with consequent dehydration, hypokale-
mia and hypomagnesemia. The decrease in GFR may be so
severe as to necessitate discontinuation of therapy, leading to
progression of the underlying disease and extension of the
hospital stay. Therefore, any maneuver that decreases the
frequency and/or severity of amphotericin B-associated neph-
rotoxicity will aid the therapeutic use of this drug. This is
especially true considering the increasing frequency of fungal
infections, which is now reported at between 5 and 12% of
hospitalized patients [4].
Several manipulations have been proposed to try and mini-
mize amphotencin B-induced nephrotoxicity. Mannitol co-
administration was once suggested as protective based on
anecdotal, observational reports [5, 6]. A small prospective and
randomized trial, however, did not support a protective effect
[7]. More recent reports suggest that liposomal preparations of
amphotericin B may have a wider margin of safety [8—10], but
the drug has not been approved for use yet, and more definitive
statements on its superiority to conventional formulations await
larger controlled trials.
The maneuver that has received attention involves adminis-
tration of a salt load in association with the amphotericin B
dose. Unfortunately, there has not been a prospective, random-
ized, placebo-controlled trial that would provide a convincing
argument for the routine use of such a protective measure. All
previous studies have been either case reports [11], retrospec-
tive studies [12, 13] or prospective non-controlled studies [12,
14]. Major difficulties are faced in attempting to interpret the
results of these studies, namely, that they were uncontrolled,
and that certain bias may have been introduced on the basis of
selection of patients, their underlying diseases, and the admin-
istration of other drugs. The randomized, placebo controlled
study would overcome these difficulties and provide a more
solid basis to make an informed clinical decision.
Studies of the influence of salt loading on amphotericin B
nephrotoxicity in the population of patients receiving the drug
in the U.S.A. have presented some difficulties in the evaluation
of such an intervention, since they involved patients who were
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severely ill with systemic diseases that diminish baseline renal
function, were immunocompromized, or were receiving con-
comitant potentially nephrotoxic therapy. The ability of ampho-
tericin B to eradicate the parasite in mucocutaneous leishma-
niasis offers a unique opportunity to assess the efficacy of salt
supplementation in a population of patients with this disease.
These patients were relatively healthy, nonimmunocompro-
mized, with normal baseline renal function, suffering from a
localized disease not involving the kidney which responds to
amphotericin B as a sole agent. In this paper, we report the
results of such a trial. The present report focuses on changes in
renal function, although measures of hematologic and hepatic
function were also assessed.
Methods
The study was conducted at the Instituto de Medicine Trop-
ical "Alexander Von Humboldt", of the Universidad Peruana
Cayetano Heredia, in Lima, Peru, where investigators have
been using amphotericin B to treat patients with mucocutane-
ous leishmaniasis, an endemic disease in the jungle areas of
inner Peru. Part of the assays and the data analyses were done
at the Division of Clinical Pharmacology, Vanderbilt Univer-
sity.
Patients with mucocutaneous leishmaniasis, 14 to 70 years
old, were considered for entry. This form of the disease,
produced by Leishmania braziliens, is confined to the nasal
mucosa, and is associated with destruction of the nasal septum
and facial disfigurement, but has no systemic involvement. The
subjects were otherwise healthy. Exclusion criteria included:
underlying diseases that prevented the administration of an
intravenous salt load; patients with serum Cr > 2 mgldl; and
patients receiving other medications. Twenty male patients
were entered into the study, and were randomized to either a
saline group or a dextrose group. All patients received ampho-
tericin B administered three times per week for 10 weeks,
starting with 15, 35, and 50 mg/dose the first week, and then
maintenance on 50 mg/dose for the remainder of therapy. The
drug was diluted in 0.5 liter 5% dextrose in water (D/W) and
administered intravenously over four hours, on Mondays,
Wednesdays, and Fridays. It was preceded by an infusion of 1.0
liter of either 0.9% sodium chloride (NaCl) or 5% D/W. Both
saline and D/W were precoded so that both patients and
investigators were blinded to the treatment received.
Initial pre-treatment evaluation included a history, physical
examination, and a disease activity score based on the extent of
the lesion. Blood samples were obtained for serum creatinine
(Cr), blood urea nitrogen (BUN), electrolytes, calcium (Ca),
magnesium (Mg), phosphorus (P), proteins, liver function tests,
prothrombin time, complete blood count, reticulocyte count
and platelets. In addition, a 24-hour urine collection was
obtained for volume, Cr, electrolytes, Ca, Mg, specific gravity,
and urinalysis. From these values creatinine clearance and
urinary excretion rates were calculated. Urinary acidification
ability was assessed using the ammonium chloride (NH4CI)
loading test. The patients received 0.1 g/kg NH4CI orally and
urine was collected hourly for three hours thereafter. If the pH
of the urine decreased below 5.5, the test was considered
normal. A baseline electrocardiogram was also obtained in all
patients.
Therapy was monitored on a weekly basis with assessment of
disease activity score, and repeat of the above-mentioned
measurements except for the hematologic, hepatic and cardiac
evaluations, which were made on a bi-weekly basis. A plasma
sample was also obtained every week for measurement of
amphotericin B levels by HPLC. The collection of plasma
samples for monitoring of therapy was performed on Monday
mornings, prior to the subsequent dose of amphotencin B.
Similarly the 24-hour urine collection were started on Sunday
morning, approximately 40 hours after the last dose of the drug,
and ended on Monday morning of each week, before the
administration of the Monday dose. Finally, tissue samples
from the diseased area were obtained, when possible, on weeks
1, 5 and 11 to test for the presence of the parasite and for
measurement of amphotericin B concentrations. Nephrotoxic-
ity of sufficient severity to cause withdrawal from the study was
defined as an increase in serum Cr to greater than 2 mgldl. In
such cases, the decision had been made to withold the subse-
quent dose of amphotericin B until the serum Cr returned
toward baseline. In addition, potassium (K) supplementation
was to be instituted when serum K levels fell to below 3
mmollliter, and the magnitude of the supplement would be
determined by the amount required to maintain K levels above
3 mmol/liter.
Patients remained hospitalized for the duration of the study
(12 weeks) and were fed a constant diet ad libitum. Water was
also unrestrained.
Values are reported as means SEM. Statistical analysis was
conducted using the Number Cruncher Statistical System
(NCSS, Kaysville, Utah, USA). Comparisons within one group
were done using one-way analysis of variance (ANOVA),
followed, when appropriate, by Duncan's range test to compare
individual time points. Comparison between the two groups
was done using ANOVA with repeated measures, one factor
being the weekly cumulative doses of amphotencin B (11
levels), and the other factor being the treatment groups (2
levels, NaCI or D/W). Finally, life survival analysis was con-
ducted using the Cox/Mantel test. All null hypotheses were two
tailed, and the criterion for significance was P < 0.05.
Results
All patients responded to therapy with amphotericin B with
remission of the disease as assessed by histologic examination,
with no difference between the two groups in the therapeutic
response. The patients reported symptomatic improvement as
early as the first week of therapy. All but two patients com-
pleted the whole course of therapy. One patient withdrew early
in the course of therapy for personal reasons and another
replaced him in the same arm of the study; the former's data are
not included in the analysis. Another patient was withdrawn
after a cumulative dose of 1000 mg (week 7), when he developed
cardiac arrhythmias.
The randomization procedure was successful in creating two
similar groups with respect to most parameters studied (Table
1). The only significant observation was a small difference in
serum Cr levels. The saline group had a higher baseline mean
serum Cr concentration than did the dextrose group (0.8 0.05
vs. 0.6 0.04 mg/dl, P < 0.01), although all subjects in both
groups were within normal limits (Fig. 1). The reason for this
difference is not clear. The urinary Na excretion rates were
relatively high compared to the usual population of patients
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Age years
Weight kg
Urine flow mi/day
Serum Cr mg/di
CcrmI/mm/I. 73 m2
Urinary Na excretion
mmo!/day
Serum K mmoi/iiter
Urinary K excretion
mmoi/day
Serum Ca mg/di
Ca excretion mg/day
Serum Mg mmoi/iiter
Urinary Mg excretion
mmoi/day
Serum P mg/dI
Specific gravity
_____________________
receiving this drug in the USA [11], but no difference existed
between the two groups.
Analysis of serum Cr over time revealed that the responses
were significantly different between the two groups. The mean
serum Cr increased over time in the dextrose group, but
remained unchanged in the saline group (Fig. 2). The greatest
increase occurred during the first week and the last three weeks
of treatment. The mean maximal increase in serum Cr during
therapy was significantly greater in the dextrose group (P =
0.01, Fig. 1). Similarly, Cr clearance decreased in the dextrose
group, but remained unchanged in the saline group, resulting in
a significantly different response over time (P < 0.05 by
ANOVA, Table 2). There was no change in weight in either
group over time. None of the patients sustained a failure event
as defined by an increase in serum Cr to >2 mgldl. However,
using more stringent criteria for defining a nephrotoxic event,
that is, a 100% increase in serum Cr, life table analysis
confirmed the presence of a significant difference between the
two groups (Fig. 3), with four patients in the dextrose group,
and none in the saline group, meeting this criterion. Since the
increase in serum Cr was small, the drug was not withdrawn in
any of the four patients.
Urinary Na, K, Ca and Mg excretion rates are presented in
Table 2. Despite the fact that these collections were started two
days after the last dose of drug and intervention, there was a
greater urinary Na excretion in the saline group over time.
Urinary K excretion was not different in the two groups and did
not change with time, while Ca excretion decreased in both
groups in a similar fashion. Urinary Mg excretion also de-
creased in both groups in a similar fashion, although this
decrease was not significant in the dextrose group because of
large variations in the baseline value.
Serum Na, Ca, P and Mg levels did not change over time in
either group. Serum K, however, sustained a significant de-
crease within the first two weeks of treatment (P < 0.0001 for
effect of dose, but no difference between groups, Fig. 4A).
When K levels reached 3 mmol/liter, K supplementation ther-
apy was instituted. This was successful in maintaining normal
or near-normal levels. Analysis of the K supplement itself
revealed marked differences between the two groups, with the
saline group requiring significantly higher supplements than the
dextrose group, being approximately 70 mmol/day higher at the
P value end of the study (P < 0.0001, Fig. 4B).
ever, each tissue sample measured did have a concurrent
measure of plasma amphotericin B concentration. Analysis of
tissue levels revealed wide variations in values, and no signifi-
cant difference was observed between the two groups (Table 3).
The plasma to tissue ratios revealed that levels in plasma were
approximately 20-fold higher than in the nasal mucosa, and that
the ratio at one week of treatment was similar to that at the end
of the course of therapy (Table 3).
Discussion
For approximately 30 years, nephrotoxicity, especially
azotemia, has been regarded as a major and sometimes invari-
able consequence of amphotericin B therapy. Early studies
reported an incidence of 80 to 90% [1]. A more recent report
suggested that almost all patients develop azotemia, with a
reduction of GFR of 20 to 60% initially, later stabilizing at 40%
of baseline values [15]. Several risk factors have been sug-
gested, including age [16], total dose [1, 17], frequency of
dosing [18, 19], underlying renal disease, co-administration of
other potentially nephrotoxic agents [13], and dehydration or a
salt conserving state [11, 12]. One of the major manipulations
that has been suggested as protective against amphotericin B
nephrotoxicity is salt supplementation [20]. However, most of
the information about the efficacy and effectiveness of this
measure has been derived from case reports, retrospective
studies, or prospective observational studies. The present re-
port is the first to test the hypothesis that salt supplementation
protects against amphotericin B-induced nephrotoxicity in a
prospective, randomized, and controlled manner.
A limiting factor in the interpretation of many previous
reports involves the complexity of the populations that were
studied. In general, patients receiving amphotericin B in the
U.S.A. are usually suffering from severe systemic fungal infec-
tions. These are frequently a consequence of debilitating dis-
eases (AIDS, cancer, diabetes) or therapeutic measures (anti-
cancer chemo- or radio therapy, cyclosporine) that result in
immunosuppression. Thus, many of these patients have other
causes of, or predisposing factors for, renal failure that may act
Table 1. Baseline characteristics in the control and saline groups(N = 10 in each)
32.5 3.3
53.4 2.3
1687 217
0.60 0.04
111.6 6.3
262 23
4.4 0.2
51.0 7.7
8.3 0.4
189 35
1.55 0,06
2.48 1.41
3.8 0.3
lOll I
Dextrose Saline
38 ÷ 2 8 NS Assessment of the specific gravity of the urine over time
52:3 1:2 NS revealed a significant and similar decrease in the two groups (P
1545 193 NS < 0.0001). Both groups sustained a slight but non-significant
0.80 0.05 <0.01 increase in the basal urinary pH. Life table analysis of the
99.1 4.9 NS response to an acid load showed a faster loss of acidification in
224 17 NS the saline group, where all subjects failed after the first week of
4.1 0.2 NS therapy. In the dextrose group, only 4 of 10 failed during the
59.4 11.0 NS first week, and by the second week all had failed. One patient in
the dextrose group regained acidification ability in the fifth
8.6 0.2 NS week. Statistical comparison of these two responses revealed a
1 54 0 04 S significant difference with P <0.005.
4:78 1:08 NS Plasma trough amphotericin B concentrations are depicted in
Figure 5. No differences were observed between the two
4.1 0.3 NS groups. Steady state was achieved in approximately eight
1014 I NS weeks, indicating an approximate half-life of two weeks. Sam-
ples of tissues received for measurement of amphotericin B
levels were not obtained from all patients due to practical
considerations of obtaining biopsies from healed lesions, and
repeat samples were not always from the same patients. How-
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Fig. 2. Serum creatinine levels in dextrose (A—A) and saline U--U)
treated groups receiving amphotericin B at 50 mg/dose 3 times weekly
for 10 weeks (N = lOin each). Two-way ANOVA revealed P < 0.01 for
interaction of intervention and dose on the response. *D < 0.05
compared to baseline.
as confounding variables when amphotericin B nephrotoxicity
is assessed. This is particularly true of patients receiving
concomittant antibacterial therapy with potentially nephrotoxic
drugs such as aminoglycosides or vancomycin. The population
of patients studied in this trial differ from the population
receiving the drug in several respects. Firstly, they suffer from
a localized, non-life threatening disease, which although se-
verely disfiguring, has virtually no systemic effects. Thus, the
patients are relatively healthy and have normal baseline renal
function. Secondly, since the disease is responsive to ampho-
tericin B as a sole agent, they do not require administration of
other potentially nephrotoxic agents. Therefore, this population
of patients offers a unique opportunity to examine the effects of
this drug and the possible benefit from salt supplementation,
free from the bias that would be introduced were a conventional
* * population chosen. However, this population also presents
some disadvantages in that it is composed of native Peruvians
who are ethnically different from the populations in whom the
drug has been most extensively studied (Caucasians). This
limits our ability to draw comparisons with previous studies. In
addition, as the results show, basal salt intake in the two groups
was relatively high, as reflected by the high baseline urinary Na
excretion rate. This may be expected to minimize the benefit
that would be derived from salt supplementation.
The results of this study are interesting. Despite a cumulative
dose of 1450 mg, none of the patients in either group sustained
a nephrotoxic response as defined by an increase in serum Cr to
>2 mg/dl. This is in contrast to reports of 60 to 70% in cases
where no salt supplementation was administered [1, 12, 15, 21],
and 0 to 12% where it was [12—141. The explanation for the
absence of a marked decrease in GFR may relate to several
factors. As the baseline data show, the initial Na excretion,
which should reflect Na intake, was high in this population,
being 262 23 mEq/day in the dextrose group and 224 17
mEq/day in the saline group. This exceeds usual values for Na
excretion reported for the U.S.A. population by approximately
100 mEq/day [111. Thus, if salt supplementation is protective,
as suggested by previous studies, this already elevated Na
intake may have accounted for the low frequency of nephro-
toxicity in the dextrose group. It should be noted that this
native Peruvian population has relatively lower body weights
than an age matched population in the U.S.A., and therefore
their serum Cr concentrations are generally lower. Therefore,
an increase in serum Cr to above 2 mg/dl may reflect a greater
loss of renal function than a similar increase in the American
population. When nephrotoxicity was defined as a 100% in-
crease in serum Cr above baseline, a clear difference between
the groups was observed, with four patients in the dextrose
group and none in the saline group developing nephrotoxicity.
This finding, in appropriately matched groups, does support the
* +
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Fig. 1. Baseline and maximum serum
creatinine concentrations achieved in two
groups of patients receiving amphotericin B
(150 mg/wk) for 10 weeks. *P < 0.05
compared to baseline; +P < 0.000! compared
to baseline. Comparison of the maximal
change in serum Cr in the two groups gave a
P = 0.01.
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Table 2. Influence of amphotericin B (150 mg/week) on creatinine clearance (Ccr), serum levels of Ca, P and Mg, urinary excretion rates of
Ma, K, Ca and Mg, specific gravity and flow rate of urine over 10 weeks in 2 groups of patients receiving I liter of either 0.9% NaCI or 5%
D/W i.v. prior to the amphotericin B dose (N = 10 in each)
Amphotericin B P value
One way Two way
Baseline Week 1 Week 4 Week 7 Week 10 ANOVA ANOVAb
CCr mi/mm/I .73 m2
Dextrose ill 6 88 9C 87 5C 94 9C 76 7C <0.01 <0.05
Saline 99±5 90±7 80±9 70±6 91±9 NS
Serum Ca mg/dl
Dextrose 8.3 0.3 8.3 0.3 8.2 0.3 8.5 0.2 8.4 0.2 NS NS
Saline 8.6 0.2 8.4 0.2 8.7 0.3 8,4 0.3 8,3 0.2 NS
Serum Mg mEq/liter
Dextrose 1.5 0.6 1.4 0.1 1.3 0.1 1.5 0.1 1.1 0.1 NS NS
Saline 1.5 0.4 1.5 0.2 1.4 0.2 1.4 0.2 1.4 0.1 NS
Serum P mg/d!
Dextrose 3.8 0.3 3.8 0.2 3.9 0.2 3.8 0.2 3.6 0.2 NS NS
Saline 4.1 0.3 4.4 0.2 3.8 0.2 3.7 0.3 3.8 0.2 NS
Urinary Na cxc. mmol/day
Dextrose 262 23 241 25 198 24 208 25 180 35 NS <0,05
Saline 224 17 215 26 222 43 220 33 270 34 NS
Urinary K cxc. mmol/day
Dextrose 55 7 48 3 48 7 53 6 49 9 NS NS
Saline 61±10 43±5 45±6 49±5 64±7 NS
Urinary Ca cxc. mg/day
Dextrose 189 35 138 19C 81 12C 98 9C 82 9C <0.0001 NS
Saline 168 31 142 IS 101 l2 99 l4C 95 l3 0.03
Urinary Mg cxc. mmol/day
Dextrose 2.5 1.4 0.8 0.5 1.3 1.1 0.1 0.1 0.2 0.1 NS NS
Saline 4.8 1.1 1.4 0.6 0.5 0.2 0.3 0.1 0.2 0.1 <0.0001
Urine flow rate liter/day
Dextrose 1.7 0.2 2.2 0.2 2.5 0.3 2.6 0.3 2.8 0.3 NS NS
Saline 1.5 0.2 2.3 0.2 2.8 0.3c 2.9 0.3c 3.1 0.3c <0.0001
Specific gravity
Dextrose 1011 1 1011 1 1008 iC 1007 IC 1005 ic <0.0001 NS
Saline 1014 2 1009 ic 1006 IC 1006 IC 1005 IC <0.0001
P < 0.05 compared to baseline using Duncan's range test, performed following a significant difference using one way ANOVACb Interaction of time and intervention (saline or dextrose) on the response
hypothesis that salt supplementation protects against ampho- 10 • U U U • U U •
tericin B-induced reductions in the GFR.
Other factors which may have contributed to the absence of
a marked decrease in the GFR could relate to ethnic differences 8
between the native Peruvian and American populations, or to
.k &
the fact that the drug was administered on an alternate day
schedule. A previous study in dogs [19] and a case report in . 6
humans [181 have suggested that alternate day therapy is
associated with a lower frequency and severity of azotemia, '
though this issue has not been addressed in a controlled 2
randomized study. Finally, one should consider the possibility 2
that the intrinsic toxicity of this agent to the kidney is actually
low when given to healthy individuals as a sole agent. It may be 2
that the very high incidence reported in the literature merely
reflects the contribution of the several factors mentioned pre-
viously to the development of nephrotoxicity, most impor- 0 250 400 300 850 1000 1150 1300 1450
tantly, the presence of an underlying systemic disease and the
co-administration of potentially nephrotoxic agents. In addi- Amphotericin B cumulative dose, mg
tion, early reports which indicated frequencies of 80 to 9tJ% [I, Fig. 3. Life table analysis for patients developing nephrotoxicity de-
16, 17] were of patients treated with excessively high doses fined as a 100% increase in baseline serum Cr level. Symbols are: (U)
saline; (A) dextrose, P < 0.03 by Cox/Mantel test.
reaching up to 5 g, which are rarely used at the present time.
The observation that salt loading conferred protection on
renal function is in agreement with previous studies. In 1983, a prior identifiable salt-conserving states. Upon receiving salt
series of five patients were reported who developed azotemia supplements, all five lowered their serum Cr and BUN levels,
when amphotericin B was administered [11]. Four of these had and amphotericin B was restarted with no further deterioration
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Amphotericin B cumulative dose, mg
Fig. 4. Serum K concentrations (A) and K supplementation given to
maintain serum K at or above 3 mmol/liter (B), in the dextrose (A A)
and saline (•----) groups (N = 10 in each). (A). P < 0.0001 for dose
only. (B). P < 0.0001 for effect of dose and intervention on response. *D
<0.05 compared to baseline.
in renal function. Another study reported that only 12% of
patients receiving ticarcillin, with its obligatory Na load of 156
mEq/day, in conjunction with amphotericin B developed neph-
rotoxicity, compared to 67% in those not receiving ticarcillin
[12]. In a companion study to the above, 2 of 20 patients
receiving 1 liter 0.9% NaCI routinely with every dose of
amphotericin B developed nephrotoxicity. Finally, a recent
report indicated that of 37 patients receiving amphotericin B
with 50 to 100 ml of 10% NaCI i.v., none developed nephrotox-
icity defined as an increase in serum Cr to >2 mg/dl [14].
The beneficial effect of salt loading, however, occurs at the
expense of hypokalemia and, perhaps, worsening tubular func-
tion. The saline group required significantly higher amounts of
K supplementation to maintain a normal serum K level. This
could reflect greater damage to the tubular cells, or simply be
the result of increased Na delivery to the distal tubule, which
itself stimulates K secretion. The absence of differences in the
urinary K excretion rate probably relates to the fact that the
urine collections were begun at least 40 hours after the last dose
of amphotericin B and the intervention. Thus, there must have
been an acute increase in urinary K excretion immediately
following each dose of amphotericin B.
Both groups sustained a similar decrease in the specific
gravity of the urine, suggesting a decreased ability to concen-
trate the urine. However, no specific challenge test was done to
assess this. The NH4CI loading test revealed a faster loss of
acidification in the saline group. While this may reflect greater
tubular toxicity in that group, it could also be a consequence of
increased potassium excretion. The greater the hypokalemia,
the greater the renal ammonia production, which with a pK of
9, interferes with maximum urinary acidification upon NH4CI
administration. In contrast, Ca and Mg excretion rates de-
creased similarly in both groups, with no change in serum Ca or
Mg levels. Once again, caution is required in interpretation of
these results since the urine collections were obtained two days
after the last dose of drug and intervention.
The plasma concentrations of amphotericin B were similar in
the two groups, as were the tissue concentrations. These results
suggest that the differences observed in renal function between
the two groups are probably not on the basis of a pharmacoki-
netic interaction between the drug and the sodium supplement.
However, an interaction at the level of the kidney cannot be
ruled out. Animal studies have shown that while plasma con-
centrations of amphotericin B are similar in salt-loaded and
salt-depleted rats treated for three weeks, the kidney to plasma
ratios are severalfold higher in salt-depleted rats which sus-
tained greater deterioration in GFR [22]. Since the kidney is not
a major route of excretion for this drug [23, 24], this difference
is presumably not a result of the greater decrease in GFR in that
group of rats. Rather, it suggests an interaction at the level of an
uptake process in the kidney, whereby the accumulation of the
drug in the renal tissue is not simply a passive process reflecting
plasma concentrations.
In summary, this study shows that the frequency and severity
of nephrotoxicity (as assessed by decreased GFR) in this
generally healthy population of patients receiving amphotericin
B is exceedingly low. Nevertheless, the slight deterioration in
GFR that did occur was more pronounced in the non-salt
supplemented group, supporting the protective effect of salt on
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Fig. 5. Plasma trough amphotericin B concentrations in the dextrose(A A) and saline (----U) groups (N = 10 in each). No significant
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Table 3. Concentrations of amphotericin B in biopsied tissue from the site of the lesion, and its plasma-to-tissue ratios in the two groups of
patients
Dextrose Saline
Week 2
(N=4)
Week 10
(N=4)
Week I
(N=5)
Week 2
(N=3) Week 10(N=6)
Tissue concentration ng/g
Plasma: tissue ratio
7.3 1.7
23.5 3.4
19.4 6.6
16.6 4.1
8.8 2.2
21.9 5.8
5.1 2.3
26.5 4.9
20.6 34
13.2 5.2
P < 0.05 compared to weeks 1 and 2
glomerular function. Although measures of tubular function
were significantly better in the dextrose group, these differ-
ences, except for hypokalemia, were mainly during the first two
to three weeks of treatment, and probably are not of practical
clinical significance. Therefore, based on the results of this and
previous studies, we recommend routine salt supplementation
with administration of amphotericin B, with special attention
being paid to serum potassium concentrations.
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